Build

GH-Peptide Administration Deep Dive — Forms, Dosing, Timing, Cycles

5 min read

GH-Peptide Administration Deep Dive — Forms, Dosing, Timing, Cycles

Provenance: educational study-synthesis (secondary source)

A clinician-style review grounding GH-peptide practical use in short-term studies + mechanism (and honest about how thin the evidence is — e.g. CJC-1295 without DAC has zero studies, so its dosing is explicitly speculative). Repeatedly stresses “educational only, in conjunction with your doctor.” Tagged [educational]; research/educational use only. Source: YouTube — _XBX3hGYD1o (Thorough structured capture; full verbatim not stored.)

Governing principle

Don’t just maximise GH. GH is pulsatile — a spike must return to a low baseline so the body switches from anabolic to repair/cleanup (longevity) pathways. Too low GH → visceral fat, less lean mass, poor recovery; too high → insulin resistance, expedited cancer progression, possibly shorter lifespan. Both low and high IGF-1/GH track higher all-cause mortality. So augment normal physiology, don’t override it — start low, go slow.

Lab monitoring (baseline → 1 month → after dose changes / end of cycle)

Fasting insulin, fasting glucose, HbA1c (insulin-resistance risk is the key downside); lipids (HDL, triglycerides — where benefit shows); IGF-1 (best GH-status marker; keep in normal range, not too high); prolactin (GHRPs can raise it — ipamorelin least, due to selectivity); thyroid (TSH/fT3/fT4); cortisol (4-pt salivary or 8 a.m.); CBC + CMP (liver/kidney/electrolytes); cancer screening (PSA + age-appropriate) before starting — GH doesn’t cause cancer but can expedite an existing one.

Forms / bioavailability — SubQ > intranasal > sublingual > oral

  • Oral: GHRH analogs ≈ 0% (never use); GHRP (ipamorelin) ~10% (dog) — still not worth it.
  • Sublingual: only a non-significant trend for GHRP-6; avoid.
  • Intranasal: sermorelin ~3–5% (up to 7% with surfactant); ipamorelin ~20% (animal). Functionally still far below SubQ.
  • SubQ (use this): tesamorelin ~4% absolute but the studied route; ipamorelin SubQ ≥80% (hexarelin analog 77%). Key insight: the pituitary lies outside the blood-brain barrier, so the goal is systemic delivery → SubQ beats intranasal. Intranasal only makes sense if specifically chasing the neuro effects (sleep/cognition/neuroprotection) from brain GHRH receptors.

Per-peptide dosing (start low, go slow; with your doctor)

  • Tesamorelin — studies use 2 mg once daily; start 1 mg (visceral fat blunts GH, so leaner people may need less); max 2 mg (never studied higher); ~$20/dose, 3–4× sermorelin’s cost. If 1 mg underperforms, add ipamorelin before going to 2 mg.
  • Sermorelin — the gentle physiologic starter. Studies: 1 mg ×2/day; only the 1 mg (not 0.5 mg) schedule significantly raised GH. Anecdotal start 200–300 mcg, work to 500 mcg, theoretical max 1 mg. If no benefit by ~500 mcg, switch to CJC-1295-no-DAC (more cost-effective) rather than maxing sermorelin.
  • CJC-1295 without DAC (modified GRF 1-29) — no studies → speculative. 29 aa, 4 changes vs sermorelin → ~4× more potent (rat). So dose ≈ sermorelin ÷ 4: start ~100–125 mcg, max ~200–250 mcg (anecdotal ~200). Half-life ~20–50 min (vs sermorelin 10–20 min). With CJC, consider maxing it before adding ipamorelin.
  • Ipamorelin — only used with a GHRH (alone → rapid desensitization; the point is GHRH+GHRP synergy). Start 100 mcg (derived: GHRP-6 1 mcg/kg IV ≈ 70 mcg → SubQ ≈ 87.5 → 100); cautious up to 200 mcg anecdotally with monitoring. Highly selective → least prolactin/cortisol/thyroid effect.

Timing — first dose at NIGHT, right before sleep

Somatostatin is lowest at night (enabling the biggest natural pulse) and night dosing causes less receptor desensitization + aids sleep. GH peaks ~30–45 min after SubQ GHRH; deep sleep starts ~30–90 min after falling asleep → inject as the last thing before sleep (or 30–45 min before your tracker’s usual deep-sleep onset). Don’t eat ~4 h prior — somatostatin doubles within 2 h of eating (fat-driven); eating 1 h before a GHRH blunts GH ~60%. Inject GHRH + ipamorelin together.

Frequency

Max the nightly dose first. A 2nd (daytime) dose is really only for CJC + ipamorelin (not tesamorelin/sermorelin). Natural daytime pulses: men ~noon & 6 p.m.; women ~11 a.m. & 4 p.m.; exercise drives a pulse (resistance: big compound lifts, moderate-heavy, <1 min rest; aerobic: above lactate threshold; mainly younger people). Ranked 2nd-dose options: (1) 15–30 min pre-fasted-morning-workout; (2) ~11 a.m. fasted 4 h, no food 60 min after; (3) morning, no workout; (4) late-afternoon/evening workout (too close to night dose → desensitization, last resort). No 3rd dose — a 2nd daytime dose failed to produce a pulse in 5/7 men.

Cycles

5 days on / 2 off (GH system isn’t fully recovered at 24 h — cellular GH pools unrestored — so days off resensitize, limit side effects, and protect insulin sensitivity/longevity). Cycle length ~3–4 months on / 1 month off (desensitization appears at 12–16 weeks; ~4 weeks off restores sensitivity, per hexarelin/sermorelin-analog data). Note: ~50% on long-term tesamorelin formed antibodies, but these didn’t blunt GH response and waned after stopping.

New compounds / candidates reinforced

Sermorelin — created with this transcript. CJC-1295 without DAC / modified GRF 1-29 — note its distinction from the DAC version (this episode is about the no-DAC form). GHRP-6, hexarelin, MK-677 still without notes.

Graph View

Backlinks